<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84866742838</prism:url><dc:identifier>SCOPUS_ID:84866742838</dc:identifier><eid>2-s2.0-84866742838</eid><pubmed-id>22543673</pubmed-id><prism:doi>10.1007/s00432-012-1231-1</prism:doi><dc:title>Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>3</citedby-count><prism:publicationName>Journal of Cancer Research and Clinical Oncology</prism:publicationName><source-id>29930</source-id><prism:issn>01715216 14321335</prism:issn><prism:volume>138</prism:volume><prism:issueIdentifier>9</prism:issueIdentifier><prism:startingPage>1551</prism:startingPage><prism:endingPage>1560</prism:endingPage><prism:pageRange>1551-1560</prism:pageRange><prism:coverDate>2012-09-01</prism:coverDate><openaccess>0</openaccess><openaccessFlag>false</openaccessFlag><dc:creator><author seq="1" auid="23976089500"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>L.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23976089500</author-url><affiliation id="112453561" href="https://api.elsevier.com/content/affiliation/affiliation_id/112453561"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><ce:para>Purpose: Multiple drug resistance limits the efficacy of numerous cytotoxic drugs used in the treatment of small cell lung cancer (SCLC). The drug efflux protein ATP-binding cassette transporter B1 (ABCB1) has an important role in this process, and its gene variability may affect chemotherapy outcomes. Patients and methods: This study aimed to evaluate the associations between ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype with progression-free survival (PFS) and overall survival (OS) in 177 SCLC patients treated with cisplatin-etoposide or cyclophosphamide-epirubicin-vincristine chemotherapy. To determine the ABCB1 genotype, allelic speciWc TaqMan® probes were used in a RT-PCR. Results: Patients carrying the G2677T/A TT + TA + AA genotypes (24 %) or the C3435T CT + TT genotypes (72 %) or the 2677T/A-3435T haplotype (40 %) had a longer PFS (Cox regression, P = 0.052, 0.037 and 0.037, respectively); these associations persisted also in multivariate analyses (Cox regression, P = 0.028, 0.037 and 0.030, respectively). Moreover, patients with the C3435T CT + TT genotypes had a longer OS both in univariate and multivariate analysis (Cox regression, P = 0.022 and 0.028, respectively). A trend toward longer OS was noted for the 2677T/A-3435T haplotype (Cox regression, P = 0.051), but its independent value was not confirmed (Cox regression, P = 0.071). Conclusions: Our study reported a possible predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype for longer PFS and OS in Caucasian SCLC patients treated with chemotherapy. However, to be implemented into routine clinical practice, ABCB1 polymorphisms require further validation. © Springer-Verlag 2012.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84866742838" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84866742838&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84866742838&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="112789909" href="https://api.elsevier.com/content/affiliation/affiliation_id/112789909"><affilname>University Clinic Maribor</affilname><affiliation-city>Maribor</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="112453561" href="https://api.elsevier.com/content/affiliation/affiliation_id/112453561"><affilname>University Hospital Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="23976089500"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>L.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23976089500</author-url><affiliation id="112453561" href="https://api.elsevier.com/content/affiliation/affiliation_id/112453561"/></author><author seq="2" auid="23473953200"><ce:initials>M.</ce:initials><ce:indexed-name>Kosnik M.</ce:indexed-name><ce:surname>Košnik</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Košnik M.</ce:indexed-name><ce:surname>Košnik</ce:surname><ce:given-name>M.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23473953200</author-url><affiliation id="112453561" href="https://api.elsevier.com/content/affiliation/affiliation_id/112453561"/></author><author seq="3" auid="36992456700"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Ovčariček T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>T.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992456700</author-url><affiliation id="112789909" href="https://api.elsevier.com/content/affiliation/affiliation_id/112789909"/></author><author seq="4" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>A.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="5" auid="36992707400"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>E.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992707400</author-url><affiliation id="112453561" href="https://api.elsevier.com/content/affiliation/affiliation_id/112453561"/></author><author seq="6" auid="7003295818"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><preferred-name><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>I.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7003295818</author-url><affiliation id="112453561" href="https://api.elsevier.com/content/affiliation/affiliation_id/112453561"/></author><author seq="7" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>T.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="112453561" href="https://api.elsevier.com/content/affiliation/affiliation_id/112453561"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>ABCB1 protein</author-keyword><author-keyword>Chemotherapy</author-keyword><author-keyword>Genetic polymorphisms</author-keyword><author-keyword>Multiple drug resistance</author-keyword><author-keyword>Small cell lung cancer</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="1306" abbrev="BIOC">Cancer Research</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2017-11-14T19:23:11.399Z</xocs:funding-addon-generated-timestamp><xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered day="01" month="07" timestamp="2019-07-01T12:27:06.000006-04:00" year="2019"/><ait:date-sort day="01" month="09" year="2012"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2013 Elsevier B.V., All rights reserved.</copyright><copyright type="Medline Descriptors">MEDLINE® is the source for the MeSH terms of this document.</copyright><itemidlist><ce:doi>10.1007/s00432-012-1231-1</ce:doi><itemid idtype="PUI">51984989</itemid><itemid idtype="EMBASE">2012567560</itemid><itemid idtype="CABS">2012300226</itemid><itemid idtype="MEDL">22543673</itemid><itemid idtype="SCP">84866742838</itemid><itemid idtype="SGR">84866742838</itemid></itemidlist><history><date-created day="27" month="04" year="2012"/></history><dbcollection>EMBASE</dbcollection><dbcollection>CABS</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword xml:lang="eng">ABCB1 protein</author-keyword><author-keyword xml:lang="eng">Chemotherapy</author-keyword><author-keyword xml:lang="eng">Genetic polymorphisms</author-keyword><author-keyword xml:lang="eng">Multiple drug resistance</author-keyword><author-keyword xml:lang="eng">Small cell lung cancer</author-keyword></author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy</titletext></citation-title><author-group><author auid="23976089500" seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>L.</ce:given-name></preferred-name></author><author auid="23473953200" seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Kosnik M.</ce:indexed-name><ce:surname>Košnik</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Košnik M.</ce:indexed-name><ce:surname>Košnik</ce:surname><ce:given-name>M.</ce:given-name></preferred-name></author><author auid="36992707400" seq="5"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>E.</ce:given-name></preferred-name></author><author auid="7003295818" seq="6"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><preferred-name><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>I.</ce:given-name></preferred-name></author><author auid="7004393140" seq="7"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>T.</ce:given-name></preferred-name></author><affiliation afid="112453561" country="svn"><organization>University Hospital Golnik</organization><address-part>Golnik 36</address-part><city-group>4204 Golnik</city-group><affiliation-id afid="112453561"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="36992456700" seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Ovčariček T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>T.</ce:given-name></preferred-name></author><affiliation afid="112789909" country="svn"><organization>University Clinic Maribor</organization><address-part>Ljubljanska ulica 5</address-part><city-group>2000 Maribor</city-group><affiliation-id afid="112789909"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>A.</ce:given-name></preferred-name></author><affiliation afid="60031106" country="svn"><organization>Faculty of Computer and Information Sciences</organization><organization>University of Ljubljana</organization><address-part>Tržaška cesta 25</address-part><city-group>1000 Ljubljana</city-group><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><correspondence><person><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname></person><affiliation country="svn"><organization>University Hospital Golnik</organization><address-part>Golnik 36</address-part><city-group>4204 Golnik</city-group><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><ce:para>Purpose: Multiple drug resistance limits the efficacy of numerous cytotoxic drugs used in the treatment of small cell lung cancer (SCLC). The drug efflux protein ATP-binding cassette transporter B1 (ABCB1) has an important role in this process, and its gene variability may affect chemotherapy outcomes. Patients and methods: This study aimed to evaluate the associations between ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype with progression-free survival (PFS) and overall survival (OS) in 177 SCLC patients treated with cisplatin-etoposide or cyclophosphamide-epirubicin-vincristine chemotherapy. To determine the ABCB1 genotype, allelic speciWc TaqMan® probes were used in a RT-PCR. Results: Patients carrying the G2677T/A TT + TA + AA genotypes (24 %) or the C3435T CT + TT genotypes (72 %) or the 2677T/A-3435T haplotype (40 %) had a longer PFS (Cox regression, P = 0.052, 0.037 and 0.037, respectively); these associations persisted also in multivariate analyses (Cox regression, P = 0.028, 0.037 and 0.030, respectively). Moreover, patients with the C3435T CT + TT genotypes had a longer OS both in univariate and multivariate analysis (Cox regression, P = 0.022 and 0.028, respectively). A trend toward longer OS was noted for the 2677T/A-3435T haplotype (Cox regression, P = 0.051), but its independent value was not confirmed (Cox regression, P = 0.071). Conclusions: Our study reported a possible predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype for longer PFS and OS in Caucasian SCLC patients treated with chemotherapy. However, to be implemented into routine clinical practice, ABCB1 polymorphisms require further validation. © Springer-Verlag 2012.</ce:para></abstract></abstracts><source country="deu" srcid="29930" type="j"><sourcetitle>Journal of Cancer Research and Clinical Oncology</sourcetitle><sourcetitle-abbrev>J. Cancer Res. Clin. Oncol.</sourcetitle-abbrev><issn type="print">01715216</issn><issn type="electronic">14321335</issn><codencode>JCROD</codencode><volisspag><voliss issue="9" volume="138"/><pagerange first="1551" last="1560"/></volisspag><publicationyear first="2012"/><publicationdate><year>2012</year><month>09</month><date-text xfab-added="true">September 2012</date-text></publicationdate></source><enhancement><classificationgroup><classifications type="CABSCLASS"><classification> <classification-code>84.1.13.2</classification-code> <classification-description>GENETICS AND MOLECULAR BIOLOGY; MOLECULAR GENETICS; Molecular Biology Techniques; Cloning techniques and PCR</classification-description> </classification><classification> <classification-code>84.5.13</classification-code> <classification-description>GENETICS AND MOLECULAR BIOLOGY; EUKARYOTIC GENETICS; Genetics and Cancer</classification-description> </classification><classification> <classification-code>87.2.9</classification-code> <classification-description>CANCER RESEARCH; TUMOUR BIOLOGY; Genetics</classification-description> </classification><classification> <classification-code>87.4.1</classification-code> <classification-description>CANCER RESEARCH; TREATMENT; Chemotherapy</classification-description> </classification><classification> <classification-code>87.5.7</classification-code> <classification-description>CANCER RESEARCH; CLINICAL INVESTIGATIONS BY ORGAN SITE; Lung</classification-description> </classification></classifications><classifications type="EMCLASS"><classification> <classification-code>15</classification-code> <classification-description>Chest Diseases, Thoracic Surgery and Tuberculosis</classification-description> </classification><classification> <classification-code>16</classification-code> <classification-description>Cancer</classification-description> </classification><classification> <classification-code>22</classification-code> <classification-description>Human Genetics</classification-description> </classification><classification> <classification-code>29</classification-code> <classification-description>Clinical and Experimental Biochemistry</classification-description> </classification><classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification></classifications><classifications type="ASJC"><classification>2730</classification><classification>1306</classification></classifications><classifications type="SUBJABBR"><classification>MEDI</classification><classification>BIOC</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>cisplatin</chemical-name><cas-registry-number>15663-27-1</cas-registry-number><cas-registry-number>26035-31-4</cas-registry-number><cas-registry-number>96081-74-2</cas-registry-number></chemical><chemical><chemical-name>cyclophosphamide</chemical-name><cas-registry-number>50-18-0</cas-registry-number></chemical><chemical><chemical-name>epirubicin</chemical-name><cas-registry-number>56390-09-1</cas-registry-number><cas-registry-number>56420-45-2</cas-registry-number></chemical><chemical><chemical-name>etoposide</chemical-name><cas-registry-number>33419-42-0</cas-registry-number></chemical><chemical><chemical-name>topotecan</chemical-name><cas-registry-number>119413-54-6</cas-registry-number><cas-registry-number>123948-87-8</cas-registry-number></chemical><chemical><chemical-name>vincristine</chemical-name><cas-registry-number>57-22-7</cas-registry-number></chemical></chemicals><chemicals source="nlm"><chemical><chemical-name>ABCB1 protein, human</chemical-name><cas-registry-number>0</cas-registry-number></chemical><chemical><chemical-name>Cisplatin</chemical-name><cas-registry-number>15663-27-1</cas-registry-number></chemical><chemical><chemical-name>Cyclophosphamide</chemical-name><cas-registry-number>50-18-0</cas-registry-number></chemical><chemical><chemical-name>Epirubicin</chemical-name><cas-registry-number>56420-45-2</cas-registry-number></chemical><chemical><chemical-name>Etoposide</chemical-name><cas-registry-number>33419-42-0</cas-registry-number></chemical><chemical><chemical-name>P-Glycoprotein</chemical-name><cas-registry-number>0</cas-registry-number></chemical><chemical><chemical-name>Vincristine</chemical-name><cas-registry-number>57-22-7</cas-registry-number></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="34"><reference id="1"><ref-info><ref-title><ref-titletext>Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0027488745</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.</ce:initials><ce:indexed-name>Arvelo F.</ce:indexed-name><ce:surname>Arvelo</ce:surname></author><author seq="2"><ce:initials>M.F.</ce:initials><ce:indexed-name>Poupon M.F.</ce:indexed-name><ce:surname>Poupon</ce:surname></author><author seq="3"><ce:initials>A.F.</ce:initials><ce:indexed-name>Goguel A.F.</ce:indexed-name><ce:surname>Goguel</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Lizard G.</ce:indexed-name><ce:surname>Lizard</ce:surname></author><author seq="5"><ce:initials>Y.</ce:initials><ce:indexed-name>Burgeois Y.</ce:indexed-name><ce:surname>Burgeois</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Arriagada R.</ce:indexed-name><ce:surname>Arriagada</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>J Canc Res Clin Oncol</ref-sourcetitle><ref-publicationyear first="1993"/><ref-volisspag><voliss volume="120"/><pagerange first="17" last="23"/></ref-volisspag></ref-info><ref-fulltext>Arvelo F, Poupon MF, Goguel AF, Lizard G, Burgeois Y, Arriagada R et al (1993) Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy. J Canc Res Clin Oncol 120:17-23</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophos-phamide</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77949539805</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Bray J.</ce:indexed-name><ce:surname>Bray</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Sludden J.</ce:indexed-name><ce:surname>Sludden</ce:surname></author><author seq="3"><ce:initials>M.J.</ce:initials><ce:indexed-name>Griffin M.J.</ce:indexed-name><ce:surname>Griffin</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Cole M.</ce:indexed-name><ce:surname>Cole</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Verrill M.</ce:indexed-name><ce:surname>Verrill</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Jamieson D.</ce:indexed-name><ce:surname>Jamieson</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Br J Cancer</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="102"/><pagerange first="1003" last="1009"/></ref-volisspag></ref-info><ref-fulltext>Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D et al (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophos-phamide. Br J Cancer 102:1003-1009</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>MDR1 polymorphism in Xuences the outcome of multiple myeloma patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">34247889831</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Buda G.</ce:indexed-name><ce:surname>Buda</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Maggini V.</ce:indexed-name><ce:surname>Maggini</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Galimberti S.</ce:indexed-name><ce:surname>Galimberti</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Martino A.</ce:indexed-name><ce:surname>Martino</ce:surname></author><author seq="5"><ce:initials>N.</ce:initials><ce:indexed-name>Giuliani N.</ce:indexed-name><ce:surname>Giuliani</ce:surname></author><author seq="6"><ce:initials>F.</ce:initials><ce:indexed-name>Morabito F.</ce:indexed-name><ce:surname>Morabito</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Br J Haematol</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="137"/><pagerange first="454" last="456"/></ref-volisspag></ref-info><ref-fulltext>Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F et al (2007) MDR1 polymorphism in Xuences the outcome of multiple myeloma patients. Br J Haematol 137:454-456</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77956962955</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Buda G.</ce:indexed-name><ce:surname>Buda</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Ricci D.</ce:indexed-name><ce:surname>Ricci</ce:surname></author><author seq="3"><ce:initials>C.C.</ce:initials><ce:indexed-name>Huang C.C.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="4"><ce:initials>R.</ce:initials><ce:indexed-name>Favis R.</ce:indexed-name><ce:surname>Favis</ce:surname></author><author seq="5"><ce:initials>N.</ce:initials><ce:indexed-name>Cohen N.</ce:indexed-name><ce:surname>Cohen</ce:surname></author><author seq="6"><ce:initials>S.H.</ce:initials><ce:indexed-name>Zhuang S.H.</ce:indexed-name><ce:surname>Zhuang</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Ann Hematol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="89"/><pagerange first="1133" last="1140"/></ref-volisspag></ref-info><ref-fulltext>Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH et al (2010) Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 89:1133-1140</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>Association of the ABCB1 gene polymorphisms 2677G &gt; T/A and 3435C &gt; T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">60549112572</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Chang H.</ce:indexed-name><ce:surname>Chang</ce:surname></author><author seq="2"><ce:initials>S.Y.</ce:initials><ce:indexed-name>Rha S.Y.</ce:indexed-name><ce:surname>Rha</ce:surname></author><author seq="3"><ce:initials>H.C.</ce:initials><ce:indexed-name>Jeung H.C.</ce:indexed-name><ce:surname>Jeung</ce:surname></author><author seq="4"><ce:initials>C.K.</ce:initials><ce:indexed-name>Im C.K.</ce:indexed-name><ce:surname>Im</ce:surname></author><author seq="5"><ce:initials>J.B.</ce:initials><ce:indexed-name>Ahn J.B.</ce:indexed-name><ce:surname>Ahn</ce:surname></author><author seq="6"><ce:initials>W.S.</ce:initials><ce:indexed-name>Kwon W.S.</ce:indexed-name><ce:surname>Kwon</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Ann Oncol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="20"/><pagerange first="272" last="277"/></ref-volisspag></ref-info><ref-fulltext>Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS et al (2009) Association of the ABCB1 gene polymorphisms 2677G &gt; T/A and 3435C &gt; T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20:272-277</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0023092594</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.E.</ce:initials><ce:indexed-name>Charlson M.E.</ce:indexed-name><ce:surname>Charlson</ce:surname></author><author seq="2"><ce:initials>P.</ce:initials><ce:indexed-name>Pompei P.</ce:indexed-name><ce:surname>Pompei</ce:surname></author><author seq="3"><ce:initials>K.L.</ce:initials><ce:indexed-name>Ales K.L.</ce:indexed-name><ce:surname>Ales</ce:surname></author><author seq="4"><ce:initials>C.R.</ce:initials><ce:indexed-name>MacKenzie C.R.</ce:indexed-name><ce:surname>MacKenzie</ce:surname></author></ref-authors><ref-sourcetitle>J Chron Dis</ref-sourcetitle><ref-publicationyear first="1987"/><ref-volisspag><voliss volume="40"/><pagerange first="373" last="383"/></ref-volisspag></ref-info><ref-fulltext>Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>GLOBOCAN 2008, cancer incidence and mortality worldwide: Iarc cancer base no</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84866236858</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Ferlay J.</ce:indexed-name><ce:surname>Ferlay</ce:surname></author><author seq="2"><ce:initials>H.R.</ce:initials><ce:indexed-name>Shin H.R.</ce:indexed-name><ce:surname>Shin</ce:surname></author><author seq="3"><ce:initials>F.</ce:initials><ce:indexed-name>Bray F.</ce:indexed-name><ce:surname>Bray</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Forman D.</ce:indexed-name><ce:surname>Forman</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Mathers C.</ce:indexed-name><ce:surname>Mathers</ce:surname></author><author seq="6"><ce:initials>D.M.</ce:initials><ce:indexed-name>Parkin D.M.</ce:indexed-name><ce:surname>Parkin</ce:surname></author></ref-authors><ref-sourcetitle>International Agency for Research on Cancer</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss issue="10"/></ref-volisspag><ref-text>Lyon</ref-text></ref-info><ref-fulltext>Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC cancer base no. 10. International Agency for Research on Cancer, Lyon</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">64649101364</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.L.</ce:initials><ce:indexed-name>Fung K.L.</ce:indexed-name><ce:surname>Fung</ce:surname></author><author seq="2"><ce:initials>M.M.</ce:initials><ce:indexed-name>Gottesman M.M.</ce:indexed-name><ce:surname>Gottesman</ce:surname></author></ref-authors><ref-sourcetitle>Biochim Biophys Acta</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="1794"/><pagerange first="860" last="871"/></ref-volisspag></ref-info><ref-fulltext>Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794:860-871</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">32944468151</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Green H.</ce:indexed-name><ce:surname>Green</ce:surname></author><author seq="2"><ce:initials>P.</ce:initials><ce:indexed-name>Soderkvist P.</ce:indexed-name><ce:surname>Söderkvist</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Rosenberg P.</ce:indexed-name><ce:surname>Rosenberg</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Horvath G.</ce:indexed-name><ce:surname>Horvath</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Peterson C.</ce:indexed-name><ce:surname>Peterson</ce:surname></author></ref-authors><ref-sourcetitle>Clin Cancer Res</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="12"/><pagerange first="854" last="859"/></ref-volisspag></ref-info><ref-fulltext>Green H, Söderkvist P, Rosenberg P, Horvath G, Peterson C (2006) mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12:854-859</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">34250825286</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.Y.</ce:initials><ce:indexed-name>Han J.Y.</ce:indexed-name><ce:surname>Han</ce:surname></author><author seq="2"><ce:initials>H.S.</ce:initials><ce:indexed-name>Lim H.S.</ce:indexed-name><ce:surname>Lim</ce:surname></author><author seq="3"><ce:initials>Y.K.</ce:initials><ce:indexed-name>Yoo Y.K.</ce:indexed-name><ce:surname>Yoo</ce:surname></author><author seq="4"><ce:initials>E.S.</ce:initials><ce:indexed-name>Shin E.S.</ce:indexed-name><ce:surname>Shin</ce:surname></author><author seq="5"><ce:initials>Y.H.</ce:initials><ce:indexed-name>Park Y.H.</ce:indexed-name><ce:surname>Park</ce:surname></author><author seq="6"><ce:initials>S.Y.</ce:initials><ce:indexed-name>Lee S.Y.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Cancer</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="110"/><pagerange first="138" last="147"/></ref-volisspag></ref-info><ref-fulltext>Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan- pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138-147</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with Wrst-line FOLFOX-4 chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650678671</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.Y.</ce:initials><ce:indexed-name>Huang M.Y.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="2"><ce:initials>M.L.</ce:initials><ce:indexed-name>Huang M.L.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="3"><ce:initials>M.J.</ce:initials><ce:indexed-name>Chen M.J.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="4"><ce:initials>C.Y.</ce:initials><ce:indexed-name>Lu C.Y.</ce:indexed-name><ce:surname>Lu</ce:surname></author><author seq="5"><ce:initials>C.F.</ce:initials><ce:indexed-name>Chen C.F.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="6"><ce:initials>P.C.</ce:initials><ce:indexed-name>Tsai P.C.</ce:indexed-name><ce:surname>Tsai</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Pharmacogenet Genomics</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="21"/><pagerange first="18" last="25"/></ref-volisspag></ref-info><ref-fulltext>Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC et al (2010) Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with Wrst-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21:18-25</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: Mdr1 (ABCB1) G2677T/A as an example</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">34250904283</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Huebener C.</ce:indexed-name><ce:surname>Hüebener</ce:surname></author><author seq="2"><ce:initials>I.</ce:initials><ce:indexed-name>Petermann I.</ce:indexed-name><ce:surname>Petermann</ce:surname></author><author seq="3"><ce:initials>B.L.</ce:initials><ce:indexed-name>Browning B.L.</ce:indexed-name><ce:surname>Browning</ce:surname></author><author seq="4"><ce:initials>A.N.</ce:initials><ce:indexed-name>Shelling A.N.</ce:indexed-name><ce:surname>Shelling</ce:surname></author><author seq="5"><ce:initials>L.R.</ce:initials><ce:indexed-name>Ferguson L.R.</ce:indexed-name><ce:surname>Ferguson</ce:surname></author></ref-authors><ref-sourcetitle>Cancer Epidemiol Biomarkers Prev</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="16"/><pagerange first="1185" last="1192"/></ref-volisspag></ref-info><ref-fulltext>Hüebener C, Petermann I, Browning BL, Shelling AN, Ferguson LR (2007) Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677T/A as an example. Cancer Epidemiol Biomarkers Prev 16:1185-1192</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0036731995</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Illmer T.</ce:indexed-name><ce:surname>Illmer</ce:surname></author><author seq="2"><ce:initials>U.S.</ce:initials><ce:indexed-name>Schuler U.S.</ce:indexed-name><ce:surname>Schuler</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Thiede C.</ce:indexed-name><ce:surname>Thiede</ce:surname></author><author seq="4"><ce:initials>U.I.</ce:initials><ce:indexed-name>Schwarz U.I.</ce:indexed-name><ce:surname>Schwarz</ce:surname></author><author seq="5"><ce:initials>R.B.</ce:initials><ce:indexed-name>Kim R.B.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Gotthard S.</ce:indexed-name><ce:surname>Gotthard</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Cancer Res</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="62"/><pagerange first="4955" last="4962"/></ref-volisspag></ref-info><ref-fulltext>Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S et al (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955-4962</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Single nucleotide polymorphisms and outcome n docetaxel-cisplatin-treated advanced non-small-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">4444256594</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Isla D.</ce:indexed-name><ce:surname>Isla</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Sarries C.</ce:indexed-name><ce:surname>Sarries</ce:surname></author><author seq="3"><ce:initials>R.</ce:initials><ce:indexed-name>Rosell R.</ce:indexed-name><ce:surname>Rosell</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Alonso G.</ce:indexed-name><ce:surname>Alonso</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Domine M.</ce:indexed-name><ce:surname>Domine</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Taron M.</ce:indexed-name><ce:surname>Taron</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Ann Oncol</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="15"/><pagerange first="1194" last="1203"/></ref-volisspag></ref-info><ref-fulltext>Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M et al (2004) Single nucleotide polymorphisms and outcome n docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194-1203</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>ABCB1 (MDR1) polymorphisms and progression-free sur-vival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">53049085702</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.E.</ce:initials><ce:indexed-name>Johnatty S.E.</ce:indexed-name><ce:surname>Johnatty</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Beesley J.</ce:indexed-name><ce:surname>Beesley</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Paul J.</ce:indexed-name><ce:surname>Paul</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Fereday S.</ce:indexed-name><ce:surname>Fereday</ce:surname></author><author seq="5"><ce:initials>A.B.</ce:initials><ce:indexed-name>Spurdle A.B.</ce:indexed-name><ce:surname>Spurdle</ce:surname></author><author seq="6"><ce:initials>P.M.</ce:initials><ce:indexed-name>Webb P.M.</ce:indexed-name><ce:surname>Webb</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Clin Cancer Res</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="14"/><pagerange first="5594" last="5601"/></ref-volisspag></ref-info><ref-fulltext>Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM et al (2008) ABCB1 (MDR1) polymorphisms and progression-free sur-vival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 14:5594-5601</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Identification of functionally variant MDR1 alleles among European Americans and African Americans</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">3042772026</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.B.</ce:initials><ce:indexed-name>Kim R.B.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="2"><ce:initials>B.F.</ce:initials><ce:indexed-name>Leake B.F.</ce:indexed-name><ce:surname>Leake</ce:surname></author><author seq="3"><ce:initials>E.F.</ce:initials><ce:indexed-name>Choo E.F.</ce:indexed-name><ce:surname>Choo</ce:surname></author><author seq="4"><ce:initials>G.K.</ce:initials><ce:indexed-name>Dresser G.K.</ce:indexed-name><ce:surname>Dresser</ce:surname></author><author seq="5"><ce:initials>S.V.</ce:initials><ce:indexed-name>Kubba S.V.</ce:indexed-name><ce:surname>Kubba</ce:surname></author><author seq="6"><ce:initials>U.I.</ce:initials><ce:indexed-name>Schwarz U.I.</ce:indexed-name><ce:surname>Schwarz</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Clin Pharmacol Ther</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="70"/><pagerange first="189" last="199"/></ref-volisspag></ref-info><ref-fulltext>Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>A "silent" polymorphism in the MDR1 gene changes substrate speciWcity</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33846504706</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Kimchi-Sarfaty C.</ce:indexed-name><ce:surname>Kimchi-Sarfaty</ce:surname></author><author seq="2"><ce:initials>J.M.</ce:initials><ce:indexed-name>Oh J.M.</ce:indexed-name><ce:surname>Oh</ce:surname></author><author seq="3"><ce:initials>I.W.</ce:initials><ce:indexed-name>Kim I.W.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="4"><ce:initials>Z.E.</ce:initials><ce:indexed-name>Sauna Z.E.</ce:indexed-name><ce:surname>Sauna</ce:surname></author><author seq="5"><ce:initials>A.M.</ce:initials><ce:indexed-name>Calcagno A.M.</ce:indexed-name><ce:surname>Calcagno</ce:surname></author><author seq="6"><ce:initials>S.V.</ce:initials><ce:indexed-name>Ambudkar S.V.</ce:indexed-name><ce:surname>Ambudkar</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Science</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="315"/><pagerange first="525" last="528"/></ref-volisspag></ref-info><ref-fulltext>Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al (2007) A "silent" polymorphism in the MDR1 gene changes substrate speciWcity. Science 315:525-528</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Predictive value of multidrug resistance proteins, topoisomerase II and ERCC1 in small cell lung cancer: A systematic review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79955466333</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname></author><author seq="3"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Kosnik M.</ce:indexed-name><ce:surname>Košnik</ce:surname></author><author seq="5"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="72"/><pagerange first="271" last="279"/></ref-volisspag></ref-info><ref-fulltext>Knez L, Sodja E, Kern I, Košnik M, Cufer T (2011) Predictive value of multidrug resistance proteins, topoisomerase II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer 72:271-279</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">10744222684</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.L.</ce:initials><ce:indexed-name>Kroetz D.L.</ce:indexed-name><ce:surname>Kroetz</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Pauli-Magnus C.</ce:indexed-name><ce:surname>Pauli-Magnus</ce:surname></author><author seq="3"><ce:initials>L.M.</ce:initials><ce:indexed-name>Hodges L.M.</ce:indexed-name><ce:surname>Hodges</ce:surname></author><author seq="4"><ce:initials>C.C.</ce:initials><ce:indexed-name>Huang C.C.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Kawamoto M.</ce:indexed-name><ce:surname>Kawamoto</ce:surname></author><author seq="6"><ce:initials>S.J.</ce:initials><ce:indexed-name>Johns S.J.</ce:indexed-name><ce:surname>Johns</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Pharmacogenetics</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="13"/><pagerange first="481" last="494"/></ref-volisspag></ref-info><ref-fulltext>Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ et al (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">66349102227</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.N.</ce:initials><ce:indexed-name>Lara Jr. P.N.</ce:indexed-name><ce:surname>Lara Jr.</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Natale R.</ce:indexed-name><ce:surname>Natale</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Crowley J.</ce:indexed-name><ce:surname>Crowley</ce:surname></author><author seq="4"><ce:initials>H.J.</ce:initials><ce:indexed-name>Lenz H.J.</ce:indexed-name><ce:surname>Lenz</ce:surname></author><author seq="5"><ce:initials>M.W.</ce:initials><ce:indexed-name>Redman M.W.</ce:indexed-name><ce:surname>Redman</ce:surname></author><author seq="6"><ce:initials>J.E.</ce:initials><ce:indexed-name>Carleton J.E.</ce:indexed-name><ce:surname>Carleton</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="27"/><pagerange first="2530" last="2535"/></ref-volisspag></ref-info><ref-fulltext>Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530-2535</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>Pharmacogenetic assessment of toxicity and outcome after platinum plus taxanes chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">35648997048</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Marsh S.</ce:indexed-name><ce:surname>Marsh</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Paul J.</ce:indexed-name><ce:surname>Paul</ce:surname></author><author seq="3"><ce:initials>C.R.</ce:initials><ce:indexed-name>King C.R.</ce:indexed-name><ce:surname>King</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Gifford G.</ce:indexed-name><ce:surname>Gifford</ce:surname></author><author seq="5"><ce:initials>H.L.</ce:initials><ce:indexed-name>McLeod H.L.</ce:indexed-name><ce:surname>McLeod</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Brown R.</ce:indexed-name><ce:surname>Brown</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="25"/><pagerange first="4528" last="4535"/></ref-volisspag></ref-info><ref-fulltext>Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxanes chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25:4528-4535</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>Toxicity and response criteria of the Eastern Cooperative Oncology Group</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0020396015</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.M.</ce:initials><ce:indexed-name>Oken M.M.</ce:indexed-name><ce:surname>Oken</ce:surname></author><author seq="2"><ce:initials>R.H.</ce:initials><ce:indexed-name>Creech R.H.</ce:indexed-name><ce:surname>Creech</ce:surname></author><author seq="3"><ce:initials>D.C.</ce:initials><ce:indexed-name>Tormey D.C.</ce:indexed-name><ce:surname>Tormey</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Horton J.</ce:indexed-name><ce:surname>Horton</ce:surname></author><author seq="5"><ce:initials>T.E.</ce:initials><ce:indexed-name>Davis T.E.</ce:indexed-name><ce:surname>Davis</ce:surname></author><author seq="6"><ce:initials>E.T.</ce:initials><ce:indexed-name>McFadden E.T.</ce:indexed-name><ce:surname>McFadden</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Am J Clin Oncol</ref-sourcetitle><ref-publicationyear first="1982"/><ref-volisspag><voliss volume="5"/><pagerange first="649" last="655"/></ref-volisspag></ref-info><ref-fulltext>Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655</ref-fulltext></reference><reference id="23"><ref-info><ref-title><ref-titletext>MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">43649098443</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.H.</ce:initials><ce:indexed-name>Pan J.H.</ce:indexed-name><ce:surname>Pan</ce:surname></author><author seq="2"><ce:initials>J.X.</ce:initials><ce:indexed-name>Han J.X.</ce:indexed-name><ce:surname>Han</ce:surname></author><author seq="3"><ce:initials>J.M.</ce:initials><ce:indexed-name>Wu J.M.</ce:indexed-name><ce:surname>Wu</ce:surname></author><author seq="4"><ce:initials>L.J.</ce:initials><ce:indexed-name>Sheng L.J.</ce:indexed-name><ce:surname>Sheng</ce:surname></author><author seq="5"><ce:initials>H.N.</ce:initials><ce:indexed-name>Huang H.N.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="6"><ce:initials>Q.Z.</ce:initials><ce:indexed-name>Yu Q.Z.</ce:indexed-name><ce:surname>Yu</ce:surname></author></ref-authors><ref-sourcetitle>Respiration</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="75"/><pagerange first="380" last="385"/></ref-volisspag></ref-info><ref-fulltext>Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ (2008) MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75:380-385</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">67749096078</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.H.</ce:initials><ce:indexed-name>Pan J.H.</ce:indexed-name><ce:surname>Pan</ce:surname></author><author seq="2"><ce:initials>J.X.</ce:initials><ce:indexed-name>Han J.X.</ce:indexed-name><ce:surname>Han</ce:surname></author><author seq="3"><ce:initials>J.M.</ce:initials><ce:indexed-name>Wu J.M.</ce:indexed-name><ce:surname>Wu</ce:surname></author><author seq="4"><ce:initials>H.N.</ce:initials><ce:indexed-name>Huang H.N.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="5"><ce:initials>Q.Z.</ce:initials><ce:indexed-name>Yu Q.Z.</ce:indexed-name><ce:surname>Yu</ce:surname></author><author seq="6"><ce:initials>L.J.</ce:initials><ce:indexed-name>Sheng L.J.</ce:indexed-name><ce:surname>Sheng</ce:surname></author></ref-authors><ref-sourcetitle>Respiration</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="78"/><pagerange first="49" last="55"/></ref-volisspag></ref-info><ref-fulltext>Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ (2009) MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78:49-55</ref-fulltext></reference><reference id="25"><ref-info><ref-title><ref-titletext>EVects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650688876</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Shitara K.</ce:indexed-name><ce:surname>Shitara</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Matsuo K.</ce:indexed-name><ce:surname>Matsuo</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Ito S.</ce:indexed-name><ce:surname>Ito</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Sawaki A.</ce:indexed-name><ce:surname>Sawaki</ce:surname></author><author seq="5"><ce:initials>H.</ce:initials><ce:indexed-name>Kawai H.</ce:indexed-name><ce:surname>Kawai</ce:surname></author><author seq="6"><ce:initials>T.</ce:initials><ce:indexed-name>Yokota T.</ce:indexed-name><ce:surname>Yokota</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Asian Pac J Cancer Prev</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="11"/><pagerange first="447" last="452"/></ref-volisspag></ref-info><ref-fulltext>Shitara K, Matsuo K, Ito S, Sawaki A, Kawai H, Yokota T et al (2010) EVects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac J Cancer Prev 11:447-452</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen independent prostate cancer treated with docteaxel</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">51649129871</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.M.</ce:initials><ce:indexed-name>Sissung T.M.</ce:indexed-name><ce:surname>Sissung</ce:surname></author><author seq="2"><ce:initials>C.E.</ce:initials><ce:indexed-name>Baum C.E.</ce:indexed-name><ce:surname>Baum</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Deeken J.</ce:indexed-name><ce:surname>Deeken</ce:surname></author><author seq="4"><ce:initials>D.K.</ce:initials><ce:indexed-name>Price D.K.</ce:indexed-name><ce:surname>Price</ce:surname></author><author seq="5"><ce:initials>J.</ce:initials><ce:indexed-name>Aragon-Ching J.</ce:indexed-name><ce:surname>Aragon-Ching</ce:surname></author><author seq="6"><ce:initials>S.M.</ce:initials><ce:indexed-name>Steinberg S.M.</ce:indexed-name><ce:surname>Steinberg</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Clin Cancer Res</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="14"/><pagerange first="4543" last="4549"/></ref-volisspag></ref-info><ref-fulltext>Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM et al (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen independent prostate cancer treated with docteaxel. Clin Cancer Res 14:4543-4549</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33645854040</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.W.</ce:initials><ce:indexed-name>Sohn J.W.</ce:indexed-name><ce:surname>Sohn</ce:surname></author><author seq="2"><ce:initials>S.Y.</ce:initials><ce:indexed-name>Lee S.Y.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="3"><ce:initials>S.J.</ce:initials><ce:indexed-name>Lee S.J.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="4"><ce:initials>E.J.</ce:initials><ce:indexed-name>Kim E.J.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="5"><ce:initials>S.I.</ce:initials><ce:indexed-name>Cha S.I.</ce:indexed-name><ce:surname>Cha</ce:surname></author><author seq="6"><ce:initials>C.H.</ce:initials><ce:indexed-name>Kim C.H.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Jpn J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="36"/><pagerange first="137" last="141"/></ref-volisspag></ref-info><ref-fulltext>Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH et al (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137-141</ref-fulltext></reference><reference id="28"><ref-info><ref-title><ref-titletext>Small-cell lung cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77954347979</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Sorensen M.</ce:indexed-name><ce:surname>Sørensen</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Pijls-Johannesma M.</ce:indexed-name><ce:surname>Pijls-Johannesma</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Felip E.</ce:indexed-name><ce:surname>Felip</ce:surname></author></ref-authors><ref-sourcetitle>Ann Oncol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss issue="SUPPL. 5" volume="21"/><pages>v120-v125</pages></ref-volisspag><ref-text>ESMO Guidelines Working Group</ref-text></ref-info><ref-fulltext>Sørensen M, Pijls-Johannesma M, Felip E, ESMO Guidelines Working Group (2010) Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v120-v125</ref-fulltext></reference><reference id="29"><ref-info><ref-title><ref-titletext>Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77951657935</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.J.</ce:initials><ce:indexed-name>Stewart D.J.</ce:indexed-name><ce:surname>Stewart</ce:surname></author></ref-authors><ref-sourcetitle>Crit Rev Oncol Hematol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="75"/><pagerange first="173" last="234"/></ref-volisspag></ref-info><ref-fulltext>Stewart DJ (2010) Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75:173-234</ref-fulltext></reference><reference id="30"><ref-info><ref-title><ref-titletext>Genomic evidence for recent positive selection at the human MDR1 gene locus</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">1942421704</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Tang K.</ce:indexed-name><ce:surname>Tang</ce:surname></author><author seq="2"><ce:initials>L.P.</ce:initials><ce:indexed-name>Wong L.P.</ce:indexed-name><ce:surname>Wong</ce:surname></author><author seq="3"><ce:initials>E.J.</ce:initials><ce:indexed-name>Lee E.J.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="4"><ce:initials>S.S.</ce:initials><ce:indexed-name>Chong S.S.</ce:indexed-name><ce:surname>Chong</ce:surname></author><author seq="5"><ce:initials>C.G.</ce:initials><ce:indexed-name>Lee C.G.</ce:indexed-name><ce:surname>Lee</ce:surname></author></ref-authors><ref-sourcetitle>Hum Mol Genet</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="13"/><pagerange first="783" last="797"/></ref-volisspag></ref-info><ref-fulltext>Tang K, Wong LP, Lee EJ, Chong SS, Lee CG (2004) Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 13:783-797</ref-fulltext></reference><reference id="31"><ref-info><ref-title><ref-titletext>Cox proportional hazards survival regression in haplotype-based association analysis using the stochastic-EM algorithm</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">7744247432</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.A.</ce:initials><ce:indexed-name>Tregouet D.A.</ce:indexed-name><ce:surname>Tregouet</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Tiret L.</ce:indexed-name><ce:surname>Tiret</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Hum Genet</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="12"/><pagerange first="971" last="974"/></ref-volisspag></ref-info><ref-fulltext>Tregouet DA, Tiret L (2004) Cox proportional hazards survival regression in haplotype-based association analysis using the stochastic-EM algorithm. Eur J Hum Genet 12:971-974</ref-fulltext></reference><reference id="32"><ref-info><ref-title><ref-titletext>MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035383769</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.M.</ce:initials><ce:indexed-name>Van Den Heuvel-Eibrink M.M.</ce:indexed-name><ce:surname>Van Den Heuvel-Eibrink</ce:surname></author><author seq="2"><ce:initials>E.A.</ce:initials><ce:indexed-name>Wiemer E.A.</ce:indexed-name><ce:surname>Wiemer</ce:surname></author><author seq="3"><ce:initials>M.J.</ce:initials><ce:indexed-name>De Boevere M.J.</ce:indexed-name><ce:surname>De Boevere</ce:surname></author><author seq="4"><ce:initials>B.</ce:initials><ce:indexed-name>Van Der Holt B.</ce:indexed-name><ce:surname>Van Der Holt</ce:surname></author><author seq="5"><ce:initials>P.J.</ce:initials><ce:indexed-name>Vossebeld P.J.</ce:indexed-name><ce:surname>Vossebeld</ce:surname></author><author seq="6"><ce:initials>R.</ce:initials><ce:indexed-name>Pieters R.</ce:indexed-name><ce:surname>Pieters</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Blood</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="97"/><pagerange first="3605" last="3611"/></ref-volisspag></ref-info><ref-fulltext>van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, van der Holt B, Vossebeld PJ, Pieters R et al (2001) MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97:3605-3611</ref-fulltext></reference><reference id="33"><ref-info><ref-title><ref-titletext>Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650944117</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Vinolas N.</ce:indexed-name><ce:surname>Viñolas</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Provencio M.</ce:indexed-name><ce:surname>Provencio</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Reguart N.</ce:indexed-name><ce:surname>Reguart</ce:surname></author><author seq="4"><ce:initials>F.</ce:initials><ce:indexed-name>Cardenal F.</ce:indexed-name><ce:surname>Cardenal</ce:surname></author><author seq="5"><ce:initials>V.</ce:initials><ce:indexed-name>Alberola V.</ce:indexed-name><ce:surname>Alberola</ce:surname></author><author seq="6"><ce:initials>J.M.</ce:initials><ce:indexed-name>Sanchez-Torres J.M.</ce:indexed-name><ce:surname>Sánchez-Torres</ce:surname></author><author seq="7"><ce:indexed-name>Et Al.</ce:indexed-name><ce:surname>Et Al.</ce:surname></author></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="71"/><pagerange first="191" last="198"/></ref-volisspag></ref-info><ref-fulltext>Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM et al (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71:191-198</ref-fulltext></reference><reference id="34"><ref-info><refd-itemidlist><itemid idtype="SGR">79955464127</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Zhou J.</ce:indexed-name><ce:surname>Zhou</ce:surname></author></ref-authors><ref-sourcetitle>Multi-drug Resistance in Cancer</ref-sourcetitle><ref-publicationyear first="2010"/><ref-text>1st edn. Humana Press, New York</ref-text></ref-info><ref-fulltext>Zhou J (2010) Multi-drug resistance in cancer, 1st edn. Humana Press, New York</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>